Lynch syndrome (LS) is the most common hereditary cancer syndrome. While identifying LS is essential, detecting cancers early in those already diagnosed is just as critical. Now, a major new initiative is tackling that challenge head-on, with leadership from one of Lynsight’s own. The PREDI-LYNCH project, a groundbreaking European research initiative, has received €13.6 million […]

We’re proud to announce that Lynsight has successfully renewed its ISO 13485:2016 certification, reinforcing our commitment to the highest standards in quality management for medical devices. This achievement reflects our dedication to excellence in every aspect of our work—from product development to patient impact. The certification confirms that Lynsight’s quality system complies with the rigorous […]